CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

Sep 15 2010

CytoGenix, Inc. (Pink sheets: CYGX-News) today announced publication of positive results of a study using CytoGenix's novel liner DNA technology.

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus. CYDBA507 is CytoGenix's avian influenza vaccine candidate which built on CytoGenix's synDNA platform and expresses influenza virus type A/H5N1 HA and NA proteins. The ability of CYDBA507 to express HA and NA proteins in human cells was confirmed in laboratory studies.

Mice immunized with CYDBA507 showed increased H5 antibody titer compared to mice receiving placebo and the presence of high titer of antibody correlated with protection against lethal challenge with influenza type A/H5N1 virus. In two efficacy studies an average of 91% (87% and 95% respectively) of animals survived challenged with lethal doses of virus compared to 0% of animals who received either placebo or an N1 expressing vaccines. Of those animals that received H5N1 vaccine but succumbed to lethal challenge all had substantially lower H5 antibody titers confirming the correlation of high antibody titer with survival.

The emergence of highly pathogenic avian influenza virus type A/H5N1 is domestic poultry and the increasing number of human cases indicates a significant threat to public health because of the potential for pandemic spread of this virus. Since 1997, infection with H5N1 has killed millions of domestic fowl in Asia resulting in significant negative economic consequences and over 300 human cases of infection have been reported to the World Health Organization, 60% of which were fatal. CytoGenix is developing CYDBA507 for both human and commercial livestock use. The development of CYDBA507 is a low cost and more effective vaccine process than other vaccine providers, making CytoGenix's product the desired vaccine process to be used.

Lex Cowsert, PhD, CEO of CYGX stated, "The results of our testing are unprecedented in the field of DNA Vaccines, with the expanding demand for both human and commercial poultry farming applications. We feel confident that these results will convert to significant revenue for CytoGenix. As we embark on a new path to create true sustainable shareholder value, we will continue to develop other products to further our company's product line."

Cy Stein, MD, PhD, Chairman of the Board of Directors of CYGX stated, "I am extremely pleased with the results and the future that it brings to CytoGenix. Through the hard work of many people, we are finally able to move forward on a positive path to financial stability. Our efforts in the field of DNA Vaccines are now able to be expanded into many other market applications in the coming years."

Stephen Udem, MD, PhD. Board of Advisors of CYGX stated, "The results are exactly what the team at CytoGenix has hoped for over these past years. With these results, the ability to deliver a low cost and more effective vaccine over conventional vaccines places CytoGenix at the forefront of our industry, I am not only excited about the results but also for what the future means to the shareholders of CytoGenix."

Source : CytoGenix